nach oben

Erschienen in:

30.01.2018 | Original Article

Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy

verfasst von: Pirus Ghadjar, MD, Daniel M. Aebersold, Clemens Albrecht, Dirk Böhmer, Michael Flentje, Ute Ganswindt, Stefan Höcht, Tobias Hölscher, Felix Sedlmayer, Frederik Wenz, Daniel Zips, Thomas Wiegel, Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO)

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Aim

Overview on the use of androgen deprivation therapy (ADT) added to salvage radiation therapy (SRT) for prostate cancer patients with biochemical recurrence after prostatectomy.

Methods

The German Society of Radiation Oncology (DEGRO) expert panel summarized available evidence published between January 2009 and May 2017, and assessed the validity of the information on outcome parameters including overall survival (OS) and treatment-related toxicity.

Results

Two randomized controlled trials and nine relevant retrospective analyses were identified. The RTOG 9601 trial showed an OS improvement for the combination of 2 years of bicalutamide and SRT compared to SRT alone after a median follow-up of 13 years. This improvement appeared to be restricted to those patients with a prostate specific antigen (PSA) level before SRT of ≥0.7 ng/mL. The GETUG AFU-16 trial showed that after a median follow-up of 5 years, the addition of 6 months of goserelin to SRT improved progression-free survival (PFS; based on biochemical recurrence) as compared to SRT alone. ADT in both trials was not associated with increased major late toxicities. Results of retrospective series were inconsistent with a suggestion that the addition of ADT improved biochemical PFS especially in patients with high-risk factors such as Gleason Score ≥8 and in the group with initially negative surgical margins.

Conclusions

ADT combined with SRT appears to improve OS in patients with a PSA level before SRT of ≥0.7 ng/mL. In patients without persistent PSA after prostatectomy and PSA levels of <0.7 ng/mL, ADT should not routinely be used, but may be considered in patients with additional risk factors such as Gleason Score ≥8 and negative surgical margins.

Han M, Partin AW, Zahurak M et al (2003) Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 169:517–523CrossRefPubMed

Ward JF, Moul JW (2005) Rising prostate-specific antigen after primary prostate cancer therapy. Nat Clin Pract Urol 2:174–182CrossRefPubMed

Wiegel T, Bartkowiak D, Bottke D et al (2015) Prostate-specific antigen persistence after radical prostatectomy as a predictive factor of clinical relapse-free survival and overall survival: 10-year data of the ARO 96-02 trial. Int J Radiat Oncol Biol Phys 91:288–294CrossRefPubMed

Tendulkar RD, Agrawal S, Gao T et al (2016) Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy. J Clin Oncol. https://doi.org/10.1200/JCO.2016.67.9647 PubMedCrossRef

Stish BJ, Pisansky TM, Harmsen WS et al (2016) Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer. J Clin Oncol 34(32):3864. https://doi.org/10.1200/jco.2016.68.3425 CrossRefPubMed

Roach M 3rd (2007) Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both? Strahlenther Onkol 183:26–28CrossRefPubMed

Bolla M, Van Tienhoven G, Warde P et al (2010) External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 11:1066–1073CrossRefPubMed

Fosså SD, Wiklund F, Klepp O et al (2016) The scandinavian prostate cancer group-7 investigators. Ten- and 15-yr prostate cancer-specific mortality in patients with nonmetastatic locally advanced or aggressive intermediate prostate cancer, randomized to lifelong endocrine treatment alone or combined with radiotherapy: final results of the Scandinavian prostate cancer group-7. Eur Urol 70:684–691CrossRefPubMed

Gandaglia G, Briganti A, Clarce N et al (2017) Adjuvant and salvage radiotherapy after radical prostatectomy in prostate cancer patients. Eur Urol 72(5):689. https://doi.org/10.1016/j.eururo.2017.01.039 CrossRefPubMed

10.

Shipley WU, Seiferheld W, Lukka HR et al (2017) Radiation with or without antiandrogen therapy in recurrent prostate cancer. N Engl J Med 376:417–428CrossRefPubMedPubMedCentral

11.

Carrie C, Hasbini A, de Laroche G et al (2016) Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol 17(6):747–756CrossRefPubMed

12.

Trock BJ, Han M, Freedland SJ et al (2008) Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy. JAMA 299:2760–2769CrossRefPubMedPubMedCentral

13.

Jang JW, Hwang WT, Guzzo TJ et al (2012) Upfront androgen deprivation therapy with salvage radiation may improve biochemical outcomes in prostate cancer patients with post-prostatectomy rising PSA. Int J Radiat Oncol Biol Phys 83:1493–1499CrossRefPubMed

14.

Goenka A, Magsanoc JM, Pei X et al (2012) Long-term outcomes after high-dose postprostatectomy salvage radiation treatment. Int J Radiat Oncol Biol Phys 84:112–118CrossRefPubMed

15.

Soto DE, Passarelli MN, Daignault S, Sandler HM (2012) Concurrent androgen deprivation therapy during salvage prostate radiotherapy improves treatment outcomes in high-risk patients. Int J Radiat Oncol Biol Phys 82:1227–1232CrossRefPubMed

16.

Parekh A, Chen MH, Graham P et al (2015) Role of androgen deprivation therapy in early salvage radiation among patients with prostate–specific antigen level of 0.5 or less. Clin Genitourin Cancer 13:e1–e6CrossRefPubMed

17.

Ervandian M, Høyer M, Petersen SE et al (2016) Salvage radiation therapy following radical prostatectomy. A national Danish study. Acta Oncol 55:598–603CrossRefPubMed

18.

Holliday EB, Kuban DA, Levy LB et al (2017) Select men benefit from androgen deprivation therapy delivered with salvage radiation therapy after prostatectomy. Prostate Cancer Prostatic Dis 20(4):389. https://doi.org/10.1038/pcan.2017.24 CrossRefPubMed

19.

Afshar-Oromieh A, Holland-Letz T, Giesel FL et al (2017) Diagnostic performance of 68 Ga-PSMA-11 (HBED-CC) PET/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging 44(8):1258–1268CrossRefPubMedPubMedCentral

20.

Henkenberens C, von Klot CA, Ross TL et al (2016) (68)Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer: Early efficacy after primary therapy. Strahlenther Onkol 192:431–439 (Jul)CrossRefPubMed

21.

Hermann RM, Christiansen H (2016) Salvage-Radiotherapie mit oder ohne Kurzzeit-Antihormonbehandlung beim PSA-Rezidiv (Literatur kommentiert). Strahlenther Onkol 192:741–744CrossRefPubMed

22.

Fossati N, Karnes RJ, Cozzarini C et al (2016) Assessing the optimal timing for early salvage radiation therapy in patients with prostate-specific antigen rise after radical prostatectomy. Eur Urol 69:728–733CrossRefPubMed

23.

Ohri N, Dicker AP, Trabulsi EJ et al (2012) Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 48:837–844CrossRefPubMed

24.

King CR (2016) The dose-response of salvage radiotherapy following radical prostatectomy: a systematic review and meta-analysis. Radiother Oncol 121:199–203CrossRefPubMed

25.

Ghadjar P, Hayoz S, Bernhard J et al (2015) Acute toxicity and quality of life after dose-intensified salvage radiation therapy for biochemically recurrent prostate cancer after prostatectomy: first results of the randomized trial SAKK 09/10. J Clin Oncol 33:4158–4166CrossRefPubMed

26.

Bartkowiak D, Thamm R, Bottke D et al (2017) Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival. Acta Oncol 17:1–6. https://doi.org/10.1080/0284186X.2017.1364869 CrossRef

Titel: Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy
verfasst von: Pirus Ghadjar, MD
Daniel M. Aebersold
Clemens Albrecht
Dirk Böhmer
Michael Flentje
Ute Ganswindt
Stefan Höcht
Tobias Hölscher
Felix Sedlmayer
Frederik Wenz
Daniel Zips
Thomas Wiegel
Prostate Cancer Expert Panel of the German Society of Radiation Oncology (DEGRO) and the Working Party Radiation Oncology of the German Cancer Society (DKG-ARO)
Publikationsdatum: 30.01.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 7/2018
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-018-1269-3

Springer Medizin

Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy

Abstract